source
- FDA moves to speed trials by reviewing AstraZeneca and Amgen data in real time, seeks public input on pilot programThe U.S. Food and Drug Administration announced a new initiative aimed at making clinical trials faster and more efficient. As a first step, the agency will begin reviewing trial data in real time…
- Health Secretary Kennedy moves to reverse FDA ban on peptide compounding, raising safety concernsHealth Secretary Robert F. Kennedy Jr. is pushing to overturn a 2023 FDA rule that stopped compounding of certain peptides, a move that could reopen a market for products such as BPC-157 and GHK-Cu…